Extract to table

such work shall be deemed to be performed on behalf of both Solstice Biomedical Devices Ltd

It is important to clarify at the outset that the Firm does not, by virtue of this engagement, represent any other affiliates, subsidiaries, parent entities, officers, directors, shareholders, members, employees, agents, or other related entities or persons of the Company, unless the Firm expressly agrees to such representation in a separate written agreement

(vi) Reporting deadline analysis, including confirmation that calendar year 2024 data must be submitted to CMS by March 31, 2025, and identification of applicable data review and dispute resolution windows

(vi) Preparation of a comprehensive remediation action plan with a detailed implementation timeline, keyed to the October 1, 2024 commercial launch date, identifying all compliance program elements that must be in place prior to the commencement of commercial activities

Any expansion of the scope of work beyond the matters described in this Section 2 must be agreed upon by the Firm and the Company in writing and may result in an adjustment to the fee estimate and fee cap set forth in Section 4 below

To provide the Company with budgetary certainty, the Firm agrees to a fee cap of $325,000 for the scope of work described in Section 2